



تقديم الدواء عبر الجلد

Transdermal Drug Delivery



Schematic block diagram of the skin with a TTS (transdermal therapeutic system) applied for systemic therapy




محتوى المقرر	
<p>Theoretical section:</p> <ul style="list-style-type: none"> - Skin products technology. - A general idea about the anatomical skin structure. - Drug absorption via the various layers of the skin. - Enhancement of drug absorption through the skin. - Semi-solid preparations - Raw material used in the manufacture of semi-solid preparations. - mechanism of action of surfactants contained in skin preparations. - Formulation development and ingredients of oleaginous and hydrophilic ointments bases. - Formulation considerations and ingredients of oil/water and water/oil creams. - Manufacturing technology of aqueous and oily gels. - Gelling agents and cross-linking agents. - rheology and flow behavior of the skin preparations. - Classification of suppositories - Applications of suppositories. - the structure of the rectum and the factors affecting drug bioavailability through the rectal route. - Suppositories bases. - The preparation methods of urethral, rectal and vaginal suppositories - Skin preparations technology and skin penetration. - Mechanism of action, formulation ingredients 	<p>القسم النظري:</p> <ol style="list-style-type: none"> 1- تكنولوجيا المستحضرات الجلدية 2- فكرة عامة عن بنية الجلد 3- امتصاص الدواء من خلال طبقات الجلد المختلفة 4- تعزيز إمتصاص الدواء عبر الجلد 5- تصنيف و مزايا المستحضرات نصف الصلبة 6- المواد الأولية الأساسية المستخدمة في تصنيع المستحضرات نصف الصلبة 7- آلية عمل المواد الفعالة على السطح في المستحضرات الجلدية 8- تركيب المراهم المحبة للماء و المحبة للزيت 9- تركيب الكريمات المحبة و الكارهة للماء 10- تكنولوجيا صناعة الهلامات المحبة و الكارهة للماء 11- البوليميرات المستخدمة في عملية التهلیم، العامل المصالب 12- دراسة انسيابية المستحضرات الجلدية 13- التصنيف الدستوري للتحاميل 14- أشكال تطبيق التحاميل 15- بنية المستقيم و العوامل المؤثرة على التوافر الحيوي 16- الأسس المستخدمة في صناعة التحاميل 17- طريقة تحضير التحاميل الشرجية، البولية، والبصبات المسيلة 18- تكنولوجيا لمستحضرات الجلدية للعبور عبر الجلد. 19- الواقيات الشمسية أنواعها و آلية عملها و تركيبها و استخدامها



تقديم الأدوية عبر الجلد

1. تعريف: حامل يحتوي كمية من المواد الفعالة والذي عندما يطبق على سطح الجلد سيحرر محتواه من المادة الفعالة إلى الدوران الجهازى بمعدل مضبوط (Controlled rate),
 ➤ أول لصاقة دواء عبر الجلد تم المصادقة عليها من قبل الـ FDI عام 1981,
 ➤ كانت موجهة لمعالجة دوام وإقياء السفر (Scopolamine)
 ➤ حالياً يوجد أكثر من 35 نوع من اللصاقات الجلدية و تحمل أكثر من 13 مادة فعالة

- **Scopolamine**
- Works as competitive antagonist of acetylcholine at the muscarinic receptor
- Product Name = Transderm Scop®
- Used for: **Motion Sickness**



تکنو 2- د. بیش

5



POTENTIAL BENEFITS OF TRANSDERMAL DRUG DELIVERY (ADVANTAGES)

- **Easy** to use.
- Avoid GIT **absorption problems** for drugs.
- Avoids FP **hepatic metabolism** of drugs.
- More improved and convenient patient compliance.
- Rapid **termination in case of toxicity** is possible.
- Self medication is possible.
- **Reduces frequency** of dosing.
- Maintains therapeutic level **for 1 to 7 days**.
- Controlled delivery resulting in more reliable and predictable blood levels.

تکنو 2- د. بیش

6




DISADVANTAGES



- Daily dose of **more than 10mg** is **not possible**.
- **Local irritation** is a major problem.
- Drug requiring **high blood levels** are **unsuitable**.
- Drug with **long half life** can not be formulated in TDDS.
- Uncomfortable to wear.
- May **not** be economical.
- Barrier **function changes** from person to person and within the same person.
- Heat, cold, sweating (perspiring) and showering prevent the **patch from sticking** to the surface of the skin for more than one day. A new patch has to be applied daily.

تكنو 2- د. بيش

7



8



TDD Patches: A System of Components

- Components must be chemically and physically compatible
- Drug formulation may or may not include excipients
- Backing: provides protection from external factors during application period
- Membrane: moderates rate of drug release
- Adhesive: maintains contact with patient's skin; incorporates drug and excipients in drug-in-adhesive TDD systems
- Liner: protects patch during storage; is removed prior to application

تکنو 2- د. بیش


11

Component/Composition

- **Matrix devices (Skin control systems)**
Active agent in polymeric membrane, adhesive, solvent, penetration enhancer, backing,
- **Reservoir devices (Membrane control systems)**
Active agent, gelling agent or excipient, solvent, penetration enhancer, adhesive, **membrane**, backing, release liner

تکنو 2- د. بیش

12



System-controlled drug delivery requires a rate-controlling element such as a polymeric membrane (Fig. 13). The membrane allows measured release of drug throughout the wearing period and provides more protection from potential drug overdose than skin-controlled delivery. Drug delivery with a system that incorporates a rate-controlling membrane produces less variability in drug input, yielding a more predictable and reproducible pharmacokinetic profile (75).

تکنو 2- د. بیش

14


Skin-controlled drug delivery devices rely on the skin's barrier properties to control the rate of drug input to the body. These devices may include a matrix or multilaminate design to act as a carrier that maintains drug in contact with the surface of the skin. Drug diffuses through the skin at a rate dictated by the concentration of drug on the skin and by the permeability of the skin to the drug. Because rate control relies completely on the skin's diffusive properties, variations in skin permeability (e.g., at different sites) may have variable effects on the delivery rate of systems without built-in control mechanisms (75).



تكنو 2- د. بيش


15

الجلد

Human skin contains 40-70 hair follicles, 200 to 250 sweat glands on every sq.cm. of skin area.







19

Skin Metabolism

The metabolic activity of the skin can alter the delivery profile and pharmacologic effects of substances that undergo percutaneous absorption. A topically applied drug can be transformed into either active or inactive metabolites that are capable of different levels of toxicity than the parent compound (27). For example, epidermal keratinocytes have the potential to metabolize propranolol via a pathway that includes formation of an aldehyde intermediate (49). Changes in the pharmacologic or toxicologic profile that result from skin metabolism may have local as well as systemic effects.

أهم التفاعلات الاستقلابية في العضوية والأعضاء المسؤولة عنها											
التفاعل العضو	أكسدة	إرجاع إماهة ألكلة أستلة انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام
		إرجاع إماهة ألكلة أستلة انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام	انضمام انضمام
رئتين	++	+	+	+	+	+	+	+	+	-	-
كبد	+	+	+	+	+	+	+	+	+	-	-
مخاطية أمعاء	+	+	+	+	+	+	+	+	+	-	-
لمعة أمعاء	-	-	-	-	-	-	-	-	-	+	+
كليتين	-	-	-	-	-	-	-	-	-	+	+
بلازما	-	-	-	-	-	-	-	-	+	-	-
جلد	+	-	-	-	-	-	-	-	-	-	-

The need for permeation enhancers is determined by the nature of the drug intended for use in the transdermal delivery system. **Highly skin-permeable drugs** agents, such **as nicotine**, do not require a permeation enhancer. The transcutaneous flux of **most hormones**, however, is low, requiring the use of a permeation enhancer such as **ethanol or triethanolamine**. These solvents permeate the skin but without rate control or occlusion, their effectiveness is brief and limited. The use of certain types of permeation enhancers has been associated with skin irritation.



العوامل المؤثرة على سرعة النفوذية عبر الجلد

- 1- تركيز الدواء المطبق
- 2- المساحة المطبقة
- 3- الخواص الفيزيائية والكيميائية للمادة الفعالة
- 4- الوزن الجزيئي
- 5- ترطيب الجلد
- 6- مكان التطبيق
- 7- المدة الزمنية

تكنو 2- د. بيش

23



مكونات ادوات التقديم عبر الجلد تتضمن:

- 1- بوليميرات حاملة (POLYMER MATRIX)
- 2- المادة الفعالة (THE DRUG)
- 3- محسنات النفوذية (PERMEATION ENHANCER)
- 4- سواغات أخرى

تكنو 2- د. بيش

24

1-POLYMER MATRIX

Following criteria to be considered in selection a polymer:

- ❖ **Molecular weight, physical of polymer must allow diffusion of drug at desired rate.**
- ❖ **Polymer must be non-reactive, inert, non-toxic, easy to manufacture, inexpensive.**
- ❖ **It should not decompose on storage of the device & not deteriorate when large amount of active ingredient is in incorporated into it.**

تکنو 2- د. بیش

25

LIST OF POLYMERS USED

NATURAL POLYMERS:

Cellulose derivatives, Zein, Gelatin, Shellac, Waxes, Gums & Natural rubber

SYNTHETIC ELASTOMER POLYBUTADIENE:

Polysiloxane, Silicon rubber, Acrylonitrile, Butyl rubber, Styrene butadiene rubber.

SYNTHETIC POLYMER

Poly vinyl alcohol, Poly vinyl chloride, Polyethylene, Poly propylene, Poly urea, PVP, Polymethacrylate

تکنو 2- د. بیش

26

Common name	Chemical name	Structure
Butyl rubber	Poly(isobutylene-isoprene)	$\text{---} \left(\text{CH}_2 - \underset{\text{CH}_3}{\overset{\text{CH}_3}{\text{C}}} \right)_x \left(\text{CH}_2 - \underset{\text{CH}_3}{\text{C}} = \text{CH} - \text{CH}_2 \right)_y \text{---}$
Halobutyl rubber ^a	Halogenated poly(isobutylene-isoprene)	$\text{---} \left(\text{CH}_2 - \underset{\text{CH}_3}{\overset{\text{CH}_3}{\text{C}}} \right)_x \left(\text{CH} = \underset{\text{CH}_3}{\overset{\text{X}}{\text{C}}} - \text{CH}_2 \right)_y \text{---}$
Ethylene-propylene rubber	Poly(ethylene-propylene)	$\text{---} \left(\text{CH}_2 - \text{CH}_2 \right)_x \left(\text{CH}_2 - \underset{\text{CH}_3}{\text{CH}} \right)_y \text{---}$
Ethylene-propylene-diene rubber	Poly(ethylene-propylene-diene)	$\text{---} \left(\text{CH}_2 - \text{CH}_2 \right)_x \left(\text{CH}_2 - \underset{\text{CH}_3}{\text{CH}} \right)_y \left(\text{diene} \right)_z \text{---}$
Silicone rubber	Polydimethylsiloxane	$\text{---} \underset{\text{CH}_3}{\overset{\text{CH}_3}{\text{Si}}} - \text{O} \text{---}$
Urethane rubber	Adipic acid-ethylene glycol polyester	$\text{HO} - \left(\text{CH}_2 \right)_2 - \text{O} - \overset{\text{O}}{\parallel} \text{C} - \left(\text{CH}_2 \right)_4 - \overset{\text{O}}{\parallel} \text{C} - \text{O} - \left(\text{CH}_2 \right)_2 - \text{OH}$
Fluoroelastomers	Polytetrafluorethylene	$\text{---} \underset{\text{F}}{\overset{\text{F}}{\text{C}}} - \underset{\text{F}}{\overset{\text{F}}{\text{C}}} \text{---}$
Natural rubber	<i>cis</i> -(1,4-Polyisoprene)	$\text{---} \left(\text{CH}_2 - \underset{\text{CH}_3}{\text{C}} = \text{CH} - \text{CH}_2 \right)_n \text{---}$
Polyisoprene rubber	<i>cis</i> -(1,4-Polyisoprene)	$\text{---} \left(\text{CH}_2 - \underset{\text{CH}_3}{\text{C}} = \text{CH} - \text{CH}_2 \right)_n \text{---}$
Neoprene rubber	Polychloroprene	$\text{---} \left(\text{CH}_2 - \underset{\text{Cl}}{\text{C}} = \text{CH} - \text{CH}_2 \right)_n \text{---}$
Styrene-butadiene rubber	Poly(butadiene-styrene)	$\text{---} \left(\text{CH}_2 - \text{CH} = \text{CH} - \text{CH}_2 \right)_x \left(\text{CH}_2 - \underset{\text{C}_6\text{H}_5}{\text{CH}} \right)_y \text{---}$
Nitrile rubber	Poly(butadiene-acrylonitrile)	$\text{---} \left(\text{CH}_2 - \text{CH} = \text{CH} - \text{CH}_2 \right)_x \left(\text{CH}_2 - \underset{\text{CN}}{\text{CH}} \right)_y \text{---}$

27

POLYMER MEMBRANE PERMEATION CONTROLLED SYSTEM

- Rate controlling membrane **made up of ethylene vinyl acetate EVA copolymer**
- A thin layer of drug compatible, **hypoallergenic adhesive polymer e.g. Silicon or polyacrylet** adhesive may be applied to the external surface.
- **Rate of drug** release affect by **varying** the polymer composition, **permeability coefficient and thickness** of rate limiting membrane and adhesive.

تکنو 2- د. بیش

28

POLYMER MEMBRANE PERMEATION CONTROLLED SYSTEM

- **Accidental breakage** of the rate controlling membrane can result in **dose dumping** or a rapid release of the entire drug content.

E.g.

- Nitroglycerine releasing trans dermal system for once a day medication for **angina**

تكنو 2- د. بيش

29

2- المواد الفعالة المفضلة للإيتاء عبر الجلد (Drug):

- 1- التي تتخرب ضمن جهاز الهضم
 - 2- التي تتخرب بالمرور الكبدي الأول
 - 3- المواد الفعالة القطبية
 - 4- غير النفوذة عبر جهاز الهضم
 - 5- ذات الأوزان الجزيئية الكبيرة (أقل من 1000 دالتون)
- يجب ان تكون المادة الفعالة محبة للماء وللدسم معاً وذات درجة انصهار منخفضة (أقل من 200 م°)



تكنو 2- د. بيش


30

Ideal properties of drug candidate

PARAMETER	PROPERTIES
Dose	Sh'd be low(< 20mg/day)
Half life	10 or less
Molecular weight	< 800
Skin permeability co- efficient	> 0.5 X 10 ⁻³ cm/ hr
Skin reaction	Non irritating & non sensitizing
Oral Bioavailability	low
Therapeutic index	low
Partition coefficient (Log P)	1-3

تکنو 2- د. بیش

31



3- محسنات النفوذية (PERMEATION ENHANCER)

مواد تضاف لزيادة وتحسين نفوذية المواد الفعالة عبر الجلد :

A. محسنات نفوذية كيميائية: (Chemical Enhancers)

➤ تعمل طريق التحريض العكوس أو تبديل الخواص الفيزيوكيميائية الطبيعية للطبقة المتقرنة لتقليل مقاومتها لنفوذ المواد الفعالة:

1. زيادة ترطيب البشرة

2. تغيير في بنية الليبيدات والبروتينات بين الخلايا

باستخدام محلات

➤ أكثر من 275 مادة استخدمت لتحسين النفوذية عبر الجلد

تكنو 2- د. بيش

33

Increased hydration of the stratum corneum

solvent action
or
denaturation

A change in the structure of the lipids and lipoproteins
in the intercellular channels

تكنو 2- د. بيش

34

More than 275 chemical compounds have been cited in the literature as skin penetration enhancers; they include :

- **Acetone, Azone ,**
- **Dimethyl Acetamide , Dimethyl Formamide**
- **Dimethyl Sulfoxide (DMSO),**
- **Ethanol,**
- **Oleic Acid,**
- **Polyethylene Glycol, Propylene Glycol ,**
- **Sodium Lauryl Sulfate .**

تکنو 2- د. بیش

35

Transdermal Controlled-Release Products and Devices

Drug	Trade Name	Type of Devices	Indication
Scopolamine	Transderm-Scop	Reservoir	Motion sickness
Nitroglycerine	Transderm-Nitro	Reservoir	Angina
	Nitro-Dur	Monolithic	
	Nitrodisc	Monolithic	
Estradiol	Estraderm	Reservoir and ethanol enhancer	Hormone treatment

تکنو 2- د. بیش

36

B. محسنات نفوذية فيزيائية: (Physical Methods)

1- ترحال أيوني (Iontophoresis)

استخدام حقل كهربائي, دراسات لمواد مثل ليدوكائين- ديكساميثازون-

امينو أسيد- ببتيدات- انسولين, لتقدم عبر الجلد.

➤ حالياً جميع هذه المواد تقدم بالحقن, لأنها تستقلب بسرعة وضعيفة

الامتصاص فموياً,


➤ أيضاً هي ضعيفة الامتصاص عبر الجلد لأنها ذات اوزان جزيئية كبيرة

وشاردية وأيضاً غير نفوذة عبر الجلد



تكنو 2- د. بيش

37

The Power Patch®



Iontophoresis:



تكنو 2- د. بيش

38

• Drug ions are delivered from the reservoir of similar polarity
 • Drug flux increases with applied current
 • Drug ions compete for current with extraneous ions




تكنو 2- د. بيش 39

B. محسنات نفوذية فيزيائية: (Physical Methods)

2- ترحال بالموجات فوق الصوتية (Sonophoresis)

دراسات لتقديم الهيدروكورتيزون والليدوكائين بشكل جل أو كريم أو لوسيون عبر الجلد باستخدام الموجات فوق الصوتية التي تقلل تماسك وصلابة الطبقة المتقرنة وبالتالي تعزيز الامتصاص عبرها

How it works



تکنو 2- د. بیش

41

Iontophoresis vs Phonophoresis



- Both Techniques Deliver Chemicals To Biologic Tissues
- **Phonophoresis** Uses **Acoustic Energy (Ultrasound)** To Drive Molecules Into Tissues
- **Iontophoresis** Uses Electrical Current To Transport **Ions** Into Tissues

تکنو 2- د. بیش

42

Products on the market, or in development include:



- **Clonidine**
- Works as an agonist of adrenaline at the presynaptic α_2 adrenergic
- Product name = Catapres-TTS®
- used to treat ***hypertension***



تکنو 2- د. بیش

43


- **Ethinylestradiol (EO)** and norelgestromin (N)
- Product name = Ortho-Evra®
- Used for **Contraception**
- Type of patch = Drug-in-Adhesive
- Frequency of application = **weekly**



تکنو 2- د. بیش

44

- **Fentanyl**
- Product Name = Duragesic®
- Used for: **Analgesia**
- Type of Patch = Drug-in-Adhesive
- Frequency of Application = **Weekly**



تکنو 2- د. بیش

45

- **Lidocaine**
- Product Name = Lidoderm®
- Used for: analgesia of postherpetic neuralgia (PHN), a painful condition caused by the varicella zoster virus (herpes zoster = shingles)



Zoster

ADAM

Lidoderm® (lidocaine 5%)

Stick it to localized pain

- ◆ Topical patch launched in 1999
 - covered by patents through 2015
- ◆ First FDA-approved drug for the treatment of the pain of post-herpetic neuralgia (PHN), a form of neuropathic pain
- ◆ Provides analgesia (without anesthesia) directly to the affected nerves


See the Possibilities

ENDO PHARMACEUTICALS

تکنو 2- د. بیش


46


Lidoderm Patch



LIDODERM works directly at the site of pain¹⁻³

- 1 Penetrates the dermis¹
- 2 Binds to receptors within sodium channels²
- 3 Stabilizes neuronal activity^{1,2}
- 4 Reduces potential for central sensitization, interrupts the pain signal²







Theoretical representation specific to LIDODERM and its effect on PHN pain. However, the mechanism of action of LIDODERM is not known.

- Type of Patch = Reservoir
- Frequency of Application = Daily


تکنو 2- د. بیش 47

- **Nicotine**
- Product name = Habitrol[®], Nicoderm – CQ[®], Nicotrol[®], Prostep[®]
- Used for: **Smoking cessation**
- Frequency of administration = **Daily**





Nicotine patch size/strength is reduced over time
Location is changed to avoid skin irritation




1st few weeks Next few weeks Last few weeks

© Healthwise, Incorporated

تکنو 2- د. بیش 48

■ Nitroglycerin

- Works by producing nitric oxide (NO), which then acts as a vasodilator
- Product Names = Nitro-Dur[®], Transderm-Nitro[®]
- Used for: **Angina**
- Type of Patch = Nitro-Dur is Drug-in-adhesive
Nitrodisc is reservoir
- Frequency of administration = **Daily**






تکنو 2- د. بیش

49

■ Estradiol

- Product Name = Alora[®], Climara[®], Esclim[®], Estraderm[®], FemPatch[®], Vivelle[®], Vivelle-DOT[®]
- Used for: **Hormone replacement**
- Type of Patch: Drug-in-adhesive
- Frequency of application = **weekly**



Estrogen replacement patch



تکنو 2- د. بیش

50

- Estradiol + Norethindrone
- Product name = CombiPatch®
- Used for: **Hormone Replacement**



تکنو 2- د. بیش

51

Iontophoretic Patches



- Iontophoretic patches use a tiny electrical current to promote flow of the drug (usually charged) through the skin.

تکنو 2- د. بیش

52